• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Johnson & Johnson wins last regulatory nod needed for Actelion acquisition

June 9, 2017 By Sarah Faulkner

Actelion, Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) said today that the European Commission approved its acquisition of Swiss biotech Actelion. The regulatory nod was the last approval needed to complete the company’s transaction.

The U.S. healthcare giant added that it expects the settlement of the $30 billion all-cash tender offer on June 16.

The EU commission set conditions to its approval, saying that development of particular Actelion insomnia drugs cannot be affected by the deal.

Actelion and Johnson & Johnson are the 2 main pharma players working on these insomnia treatments and if 1 program was halted, there wouldn’t sufficient competition, according to the commission.

Johnson & Johnson offered to pay $280 per share for Actelion in January and the deal was approved unanimously by both boards of directors.

As part of the transaction, Actelion plans to spin out its drug discovery branch and early-stage clinical development assets into a Swiss biopharmaceutical company called Idorsia Ltd, led by Actelion CEO Jean-Paul Clozel. Shares in Idorsia are expected to list on the SIX Swiss Exchange on the day of the tender offer’s settlement.

J&J will initially hold 16% of Idorsia shares, the company said.

The 2 companies were in talks for months before reaching the all-cash deal in January. Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last year.

Filed Under: Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS